Clinical Pharmacokinetics of the Angiotensin Converting Enzyme Inhibitors

[1]  C. Dollery,et al.  Drug treatment of heart failure. , 1985, British heart journal.

[2]  D. DiPette,et al.  Enalaprilat, an intravenous angiotensin‐converting enzyme inhibitor, in hypertensive crises , 1985, Clinical pharmacology and therapeutics.

[3]  J. Farmer,et al.  Pharmacokinetics and Pharmacodynamics of Enalapril in Patients with Congestive Heart Failure and Patients with Hypertension , 1985, Journal of cardiovascular pharmacology.

[4]  B. Karlberg,et al.  Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake. , 1985, Journal of cardiovascular pharmacology.

[5]  J. Laragh,et al.  Immediate converting-enzyme inhibition with intravenous enalapril in chronic congestive heart failure. , 1985, The American journal of cardiology.

[6]  R. Davies,et al.  Enalapril worldwide experience. , 1984, The American journal of medicine.

[7]  P. Plouin,et al.  Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. , 1984, British journal of clinical pharmacology.

[8]  J. Cohn,et al.  Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. , 1984, Circulation.

[9]  H. Rotmensch,et al.  BIOAVAILABILITY OF ENALAPRIL MALEATE , 1984 .

[10]  K. Swedberg,et al.  Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations. , 1983, Journal of the American College of Cardiology.

[11]  C. Johnston,et al.  Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition. , 1983, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[12]  J. Laragh,et al.  Renin system activity as a determinant of response to treatment in hypertension and heart failure. , 1983, Hypertension.

[13]  R. Cody,et al.  Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure. , 1983, Journal of the American College of Cardiology.

[14]  E. Ulm.  Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man. , 1983, Drug metabolism reviews.

[15]  R. Cody,et al.  Captopril kinetics in chronic congestive heart failure , 1982, Clinical pharmacology and therapeutics.

[16]  J. Biollaz,et al.  Enalapril maleate and a lysine analogue (MK-521): disposition in man. , 1982, British journal of clinical pharmacology.

[17]  J. Reid,et al.  Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. , 1982, British journal of clinical pharmacology.

[18]  J. Biollaz,et al.  Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. , 1982, British journal of clinical pharmacology.

[19]  S. Singhvi,et al.  Renal handling of captopril: Effect of probenecid , 1982, Clinical pharmacology and therapeutics.

[20]  B. Swanson,et al.  Effects of enalapril, a new converting enzyme inhibitor, in hypertension , 1982, Clinical pharmacology and therapeutics.

[21]  O. Drummer,et al.  Pharmacokinetic properties of captopril after acute and chronic administration to hypertensive subjects. , 1982, The American journal of cardiology.

[22]  J. M. Shaw,et al.  Effect of Food on the Bioavailability of Captopril in Healthy Subjects , 1982, Journal of clinical pharmacology.

[23]  E. M. Symonds,et al.  The effect of captopril (SQ14,225) upon mother and fetus in the chronically cannulated ewe and in the pregnant rabbit. , 1982, The Journal of physiology.

[24]  E. Ulm,et al.  The physiological disposition and metabolism of enalapril maleate in laboratory animals. , 1982, Drug metabolism and disposition: the biological fate of chemicals.

[25]  K. Iseki,et al.  Captopril (SQ 14225) clearance during hemodialysis treatment. , 1981, Clinical nephrology.

[26]  J. M. Shaw,et al.  Pharmacokinetics of captopril in dogs and monkeys. , 1981, Journal of pharmaceutical sciences.

[27]  J. Biollaz,et al.  ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421". , 1981, The Lancet.

[28]  H. Shindo,et al.  In vitro studies on the metabolic pathway of SQ 14225 (Captopril) and mechanism of mixed disulfide formation. , 1981, Journal of pharmacobio-dynamics.

[29]  K. Iseki,et al.  Blood Concentration and Urinary Excretion of Captopril (SQ 14,225) in Patients with Chronic Renal Failure , 1981, Hypertension.

[30]  W. Louis,et al.  High-performance liquid chromatographic analysis of captopril in plasma. , 1981, Journal of pharmaceutical sciences.

[31]  J. Biollaz,et al.  Three new long‐acting converting‐enzyme inhibitors: Relationship between plasma converting‐enzyme activity and response to angiotensin I , 1981, Clinical pharmacology and therapeutics.

[32]  C. A. Stone,et al.  Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. , 1981, The Journal of pharmacology and experimental therapeutics.

[33]  P. Fleiss,et al.  Captopril in Human Blood and Breast Milk , 1981, Journal of clinical pharmacology.

[34]  Z. Horovitz.  Angiotensin converting enzyme inhibitors: Mechanisms of action and clinical implications , 1981 .

[35]  J. Cohn,et al.  Acute and Long‐term Response to an Oral Converting‐enzyme Inhibitor, Captopril, in Congestive Heart Failure , 1980, Circulation.

[36]  S. Singhvi,et al.  Disposition of captopril in normal subjects , 1980, Clinical pharmacology and therapeutics.

[37]  E. Sonnenblick,et al.  Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. , 1979, The New England journal of medicine.

[38]  J. Cohn,et al.  Role of the Renin-Angiotensin System in the Systemic Vasoconstriction of Chronic Congestive Heart Failure , 1978, Circulation.